Investor Presentaiton

Performance: Vaccines +17%¹ Shingrix delivers record £3bn sales; meningitis exceeds £1bn ⚫ US: Higher retail and non-retail demand, strong commercial execution and favourable channel inventory movements ⚫ EU and International: Germany and China contributed strongly, both growing >100% New market launches: Nine launches in 2022. On track for >35 countries by 2024 Sales (£m) Shingrix sales by geography 3,500 3,000 2,500 2,000 1,500 1,000 500 ⚫ Sales ambition: Confident to double Shingrix sales by 20262 Absolute values at AER; changes at CER, unless stated otherwise. 1. Excluding pandemic adjuvant sales 2. Ambition uses 2020 as the base year GSK 0 2018 2019 2020 2021 2022 US Europe International 17

View entire presentation